Atogepant received FDA approval on September 27, 2021 [1].
When does Atogepant's exclusivity expire?
Atogepant's initial patent protection is set to expire in 2037 [2]. However, patent expiry dates can be complex and subject to challenges and extensions [2].
What is Atogepant used for?
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults [1]. It is taken orally [1].
How does Atogepant work?
As a CGRP receptor antagonist, atogepant works by blocking the activity of CGRP, a molecule that plays a role in migraine pathophysiology. By inhibiting CGRP, it is thought to reduce the frequency of migraine attacks [1].
What are the approved indications for Atogepant?
Atogepant is approved for the preventive treatment of episodic migraine in adults [1].
Who manufactures Atogepant?
AbbVie manufactures Atogepant [1].
How does Atogepant compare to other migraine preventatives?
Atogepant is an oral CGRP antagonist, distinguishing it from injectable CGRP monoclonal antibodies. While the exact comparative efficacy and safety profiles with other classes of migraine preventatives, including oral medications and injectable biologics, are subject to ongoing research and clinical experience, its oral formulation offers a different administration route for patients [1].
What clinical data supported Atogepant's FDA approval?
FDA approval was based on data from two Phase 3 studies, PROGRESS 1 and PROGRESS 2, which evaluated the safety and efficacy of atogepant in adults with episodic migraine [1].
Are there any safety concerns with Atogepant?
Common side effects reported include upper respiratory tract infection, nausea, and fatigue [1]. Patients and healthcare providers consider potential side effects when determining treatment plans.
What is the pricing of Atogepant?
Specific pricing information can vary and is often subject to insurance coverage and pharmacy benefits. Patients and providers typically consult DrugPatentWatch.com for information regarding drug pricing and patent exclusivity [2].